SERIES B WARRANT to purchase ordinary shares represented by american depositary sharesAkari Therapeutics PLC • September 14th, 2022 • Pharmaceutical preparations
THIS SERIES B WARRANT to purchase ordinary shares represented by American depositary shares (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●], 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [●], 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), up to ______ ordinary shares, par value $0.0001 per share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) represented by ______ American Depository Shares (“ADSs,” each ADS representing one hundred (100) Ordinary Shares (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant sha
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 14th, 2022 • Akari Therapeutics PLC • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 12, 2022, between Akari Therapeutic, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser,” and collectively the “Purchasers”).
